Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UTS2R | Q9UKP6 | 10/20 | 0.42 |
| ▸ | MAPT | P10636 | 5/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | AURKA | O14965 | 1/20 | 0.37 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.35 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10476392 | 0.95 | UTS2R (0.47) | UTS2RMAPTKDM4ETDP1NPSR1 | |
| SCHEMBL3234013 | 0.94 | UTS2R (0.43) | UTS2RMAPTKDM4ETDP1NPSR1 | |
| SCHEMBL1496869 | 0.93 | UTS2R (0.41) | UTS2RSMN1; SMN2ATMROCK2ROCK1 | |
| SCHEMBL3224956 | 0.89 | UTS2R (0.48) | UTS2RMAPTKDM4ETDP1NPSR1 | |
| SCHEMBL1496836 | 0.89 | UTS2R (0.39) | UTS2RROCK2ROCK1 | |
| SCHEMBL1496837 | 0.88 | UTS2R (0.46) | UTS2RAURKAATMROCK2ROCK1 | |
| SCHEMBL1497089 | 0.88 | UTS2R (0.42) | UTS2RMAPTMEN1ALDH1A1LMNA | |
| SCHEMBL11899970 | 0.87 | UTS2R (0.59) | UTS2RALDH1A1SMN1; SMN2ROCK2ROCK1 | |
| SCHEMBL3226027 | 0.87 | UTS2R (0.42) | UTS2RMAPTMEN1KMT2AATM | |
| SCHEMBL3218967 | 0.87 | UTS2R (0.42) | UTS2RMAPTALDH1A1ATMROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120202808-A1 | NOVEL THIOPHENEDIAMINE DERIVATIVE HAVING UREA STRUCTURE | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2012-08-09 | — | — | US | disclosed |
| EP-2292611-B1 | NOVEL THIOPHENEDIAMINE DERIVATIVE HAVING UREA STRUCTURE | SANTEN PHARMACEUTICAL CO LTD (JP) | 2012-07-25 | — | — | EP | disclosed |
| EP-2292611-A1 | NOVEL THIOPHENEDIAMINE DERIVATIVE HAVING UREA STRUCTURE | Santen Pharmaceutical Co., Ltd (JP) | 2011-03-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202808-A1 | NOVEL THIOPHENEDIAMINE DERIVATIVE HAVING UREA STRUCTURE | CBR1, NAT1, PRMT1 | UTS2R 195/4885MAPT 4667/4885KDM4E 2885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.